Clinical Trial Update: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of magrolimab in combination therapy for locally advanced or metastatic triple-negative breast cancer has been terminated and results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Magrolimab (magrolimab)

Snippet

Sponsor: Gilead Sciences | Conditions: Triple-Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-03